How is AI changing pharmaceutical content creation?

Anthony Stackman ·

AI is changing pharmaceutical content creation — accelerating production, enabling personalisation at scale, and shortening the path from scientific data to published material. The shift is already underway across medical affairs, commercial teams, and agency workflows. But it is more nuanced than the headlines suggest. The questions below unpack what AI can and cannot do in pharma content, where the risks lie, and how the industry is adapting.

What types of pharmaceutical content can AI actually generate?

AI can generate a broad range of pharmaceutical content: medical education materials, congress summaries, slide decks, patient-facing copy, social media content, email sequences, and first-draft clinical summaries. Generative AI tools are particularly effective at producing structured, templated content quickly, especially when trained on relevant scientific source material.

The content types best suited to AI assistance tend to share one characteristic: they follow predictable formats. Congress abstracts, disease awareness copy, and MSL leave-behind materials all have defined structures that AI can populate efficiently. Where AI is less reliable is in content that demands genuine scientific interpretation, strategic framing, or the kind of creative judgment that separates a compelling narrative from a technically accurate but flat document.

AI is also expanding into localisation and modular content adaptation — taking a core global asset and reformatting it for different markets, audiences, or regulatory environments. This is one of the more practical applications, reducing manual effort while keeping core scientific messaging intact.

How does AI handle regulatory compliance in pharma content?

It does not — not independently. Current AI tools cannot reliably apply ABPI, FDA, or EMA promotional codes without human oversight, and they are not trained to flag every jurisdiction-specific requirement. Compliance in pharmaceutical content creation remains a human responsibility. AI is a drafting assistant, not a regulatory gatekeeper.

Some platforms are developing compliance-aware features — flagging promotional language, checking reference alignment, identifying missing fair balance statements. These are useful quality-control aids, but they are not substitutes for a qualified medical or regulatory reviewer. The risk of over-relying on AI for compliance checking is significant: errors in pharma content can carry serious regulatory and reputational consequences.

The more productive approach is to treat AI as a first-pass drafting tool and build human compliance review into the workflow at every stage where regulatory requirements apply. This is how most experienced medcomms teams are working in 2026 — integrating AI into production pipelines without removing the human checkpoints that protect scientific and regulatory integrity.

What’s the difference between AI-assisted and AI-generated pharma content?

AI-assisted pharma content is produced primarily by human writers who use AI tools to support specific tasks — generating outlines, checking consistency, or suggesting alternative phrasing. AI-generated content is produced predominantly by an AI system, with humans reviewing and editing the output. The distinction matters because it determines where scientific and strategic judgment sits in the workflow.

In medical communications, this difference has practical implications for quality, accountability, and regulatory risk. AI-assisted content benefits from the scientific literacy, therapeutic area knowledge, and strategic instincts of experienced medical writers, with AI accelerating parts of the process. AI-generated content, even when reviewed, can carry subtle errors in scientific framing that a non-specialist reviewer might miss.

Most reputable agencies and pharma companies are currently working in an AI-assisted model rather than a fully AI-generated one. The volume and speed benefits are real, but the complexity of pharmaceutical content — particularly in regulated promotional and medical education contexts — means that human expertise remains central to producing work that is accurate, strategically sound, and appropriate for its audience.

How is AI changing the role of medical writers?

AI is shifting the medical writer’s role away from document production and towards scientific oversight, strategic editing, and quality assurance. Rather than spending most of their time on first drafts, experienced medical writers are increasingly directing AI output, interrogating its accuracy, and applying the clinical and strategic judgment that AI tools cannot replicate.

This is not a straightforward reduction in workload. Reviewing and correcting AI-generated drafts often requires more scientific attention than producing a draft from scratch, because errors can be subtle and the text can appear authoritative even when it is not. Medical writers who understand this dynamic are becoming more valuable — their ability to evaluate AI output critically is now a core professional skill.

The strategic dimension of the role is also expanding. As AI handles more routine content production, medical writers are being asked to contribute more to content architecture, audience strategy, and scientific narrative development. For agencies working across medical affairs and commercial teams, this shift is an opportunity to position medical writers as strategic assets rather than production resources.

What are the biggest risks of using AI for pharmaceutical content?

The biggest risks are scientific inaccuracy, regulatory non-compliance, loss of strategic nuance, and data security. Each is manageable with the right governance, but none should be underestimated — particularly in therapeutic areas where a content error carries consequences beyond reputational damage.

  • Hallucination and factual error: Generative AI tools can produce confident-sounding content that contains fabricated citations, misrepresented data, or inaccurate clinical claims. Without robust expert review, these errors can reach publication.
  • Regulatory misalignment: AI tools are not trained on live regulatory codes and cannot reliably distinguish between compliant and non-compliant promotional language across different markets.
  • Loss of scientific nuance: AI tends to flatten complex scientific arguments into accessible but sometimes oversimplified language, which can be inappropriate in medical education or payer-facing contexts.
  • Data security and confidentiality: Inputting unpublished clinical data, proprietary research, or commercially sensitive information into public AI tools carries real risk of data exposure, depending on the platform’s terms of use.
  • Homogenisation of content: Heavy reliance on AI can produce content that is technically adequate but strategically undifferentiated, reducing the creative and scientific distinctiveness that defines strong medical communications.

The agencies and pharma teams managing these risks most effectively are those that have established clear governance frameworks: defining which content types are appropriate for AI assistance, what review processes apply, and which platforms are approved for use with sensitive data.

Which AI tools are pharma companies and agencies using for content?

Pharma companies and agencies are using a combination of general-purpose large language models and specialist platforms built for life sciences content. The most commonly used general tools include GPT-4-class models accessed via enterprise APIs, Claude, and Gemini. Specialist platforms with pharma-specific features are also gaining traction, particularly those with built-in reference checking, compliance flagging, and modular content workflows.

On the agency side, tools like Jasper, Writer, and Notion AI are used for consumer and commercial content, while more technically demanding medical affairs and regulatory content tends to rely on enterprise LLM deployments with tighter data controls. Some larger pharma companies are building proprietary AI environments to ensure that unpublished data and commercially sensitive material never enters a public model.

Tool selection is increasingly a strategic decision rather than a purely technical one. Factors that matter include data security architecture, the ability to fine-tune models on therapeutic area content, integration with existing content management systems, and the quality of human-in-the-loop review functionality. No single tool currently does all of this well, which is why most organisations are working with combinations of platforms rather than a single AI solution.

How Wizzard approaches AI in pharmaceutical content strategy

We use AI to support, not replace, the scientific and strategic expertise of our team. For pharmaceutical clients working through the opportunities and risks of generative AI, that means building AI into production in ways that are genuinely useful — not just fast.

  • AI-assisted content production with qualified medical writer oversight at every stage
  • Strategic content architecture that ensures AI output serves a clear scientific and commercial purpose
  • Creative direction that prevents AI from flattening the distinctiveness of a brand’s scientific narrative
  • Governance frameworks that define appropriate AI use across different content types and regulatory environments
  • Integrated medcomms and consumer advertising expertise, so content works as hard scientifically as it does creatively

If you are working through how AI fits into your pharmaceutical content strategy, we would be glad to talk it through. Get in touch to explore what a more considered, human-led approach could look like for your team.

Related Articles